Samus Therapeutics Announces Publication of Communications Biology Study on Importance of Epichaperome Inhibition to Improve Cancer Cell Vulnerability


BOSTON, December 1, 2021 / PRNewswire / – Samus Therapeutics, Inc. (“Samus Therapeutics” or the “Company”), a private company, Bostonbiopharmaceutical company based on the development of epichaperoma inhibitors to treat cancer and diseases of the central nervous system (CNS), today announced the publication of 25 November 2021 of an article opened in Communications biology on how inhibition of the epichaperome by zelavespib (PU-H71) may increase the vulnerability of cancer cells to traditionally poorly performing treatments.

The article, “Pharmacologically Controlling Protein-Protein Interactions Via Epichaperomas for Therapeutic Vulnerability in Cancer,” reported that PU-H71 may dramatically increase the sensitivity of pancreatic cell lines or extracts from patients’ tumors to established treatments. . It also demonstrates a direct link between the survival of cancer cells and the formation of epichaperomas, and between the vulnerability of cancer cells and the disruption of epichaperomas by PU-H71. In view of these results, the authors propose a therapeutic strategy using PU-H71 to induce a state of vulnerability to the drugs currently used and thus improve their effectiveness.

“It is well known that cancer cells are continually evolving and acquiring the ability to evade the effects of established therapies,” said Barbara wallner, PhD, Scientific Director of Samus Therapeutics. “Epichaperomas, tight protein complexes that act as multimolecular scaffolds, mediate alterations in disease-associated protein-protein interactions and pathologically reshape cellular processes. Inhibition of epichaperomas with PU-H71 disrupts the activity of the cells. epichaperomas, causes structural dissociation and induces cancer cell death. “

“These findings that PU-H71 can work synergistically with established therapies to potentially improve their efficacy align with our current clinical development strategy evaluating the compound in hematologic malignancies,” added Dr. Wallner.

Disclosures: The study was led by Gabriela Chiosis, PhD, a member of the Sloan Kettering Institute’s Chemical Biology Program at Memorial Sloan Kettering Cancer Center. Dr. Chiosis owns intellectual property and financial interests related to Samus Therapeutics. Memorial Sloan kettering holds intellectual property rights and associated interests under license agreements between Memorial Sloan Kettering and Samus Therapeutics.

About Samus Therapeutics

Samus Therapeutics, Inc. is a privately held, Bostonbiotechnology company based on finding solutions to important unmet medical needs in cancer and neurodegenerative diseases through a novel approach to protein degradation and restoration of normal cellular pathways. Samus has a large proprietary technology platform with two leading clinical-stage small molecules (zelavespib and icapamespib) targeting recurrent malignant glioma, myeloproliferative neoplasm and neurodegenerative disorders including ALS and Alzheimer’s disease.

This press release contains certain forward-looking information about Samus Therapeutics, Inc. that is intended to be safe harbor for “forward-looking statements” provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts and, in some cases, can be identified by words such as “may”, “will”, “could”, “expects”, “plans”, “Anticipates,” ““ and “believes.” These statements include, but are not limited to, statements regarding progress, timing and results preclinical and clinical trials involving the Company’s drug candidates, and the advancement of The company’s research and development programs. All of these statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, which could cause actual results to differ materially from those expressed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to, whether any of our drug candidates will progress further through the preclinical or clinical trial process and if and when, if any, they will receive final approval from the Food and United States Drug Administration or equivalent. foreign regulatory agencies, whether our products will be marketed successfully if approved; the strength and enforceability of our intellectual property rights; and competition from other pharmaceutical and biotechnology companies. Although Samus Therapeutics may choose to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to update or revise any forward-looking statements contained in this press release, whether as a result of new information or future events, except as required by law.

SOURCE Samus Therapeutics, Inc.

Related links

http://samustherapeutics.com


Comments are closed.